The global gastrointestinal drugs market is predicted to touch USD 59,300 million at a 4.9?GR between 2019- 2025, reveals the new Market Research Future (MRFR) report. Gastrointestinal (GI) diseases affect the pancreas, gallbladder, liver, esophagus, rectum, large intestine, and stomach. Some of its symptoms include constipation, bloating, indigestion, heartburn, and others. Gastrointestinal drugs, simply put, are medicines utilized to treat irritable bowel syndrome, constipation, hemorrhoids, perianal infections and fissures, diverticular disease, and ulcerative colitis.
Various factors are adding to the global gastrointestinal drugs market share. These factors, as per the new MRFR report, include rising prevalence of gastrointestinal diseases worldwide, increasing investments in research for the development & expansion of gastrointestinal drugs, growing knowledge regarding the accessibility of the treatments and healing process, and technological advances in the treatment process. Additional factors adding market growth include rising awareness about gastrointestinal disease & availability of treatments, emerging generic drugs owing to its cost-effectiveness, increasing cases of irritable bowel syndrome, development in biologics, increasing cases of rectal related diseases, and the increasing number of tumors & surgeries.
On the contrary, high cost of raw materials, the increasing presence of counterfeit drugs, and certain side effects related to the drugs such as depression, dizziness, fatigue, constipation, flatulence, abdominal pain, diarrhea, nausea, and headache may limit the gastrointestinal drugs market growth over the forecast period.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/558
The MRFR report provides an inclusive segmental analysis of the global gastrointestinal drugs market based on end user, disease type, route of administration, and drug category.
By drug category, the gastrointestinal drugs market is segmented into anti-inflammatory drugs, antiemetic, laxatives and antidiarrheal, acid neutralizers, and others. Acid neutralizers are again segmented into proton pump inhibitors, H2 antagonists, antacids, and others. Of these, antacids will lead the market over the forecast period for its increasing demand owing to its easy availability and people’s unhealthy imbalance eating habits.
By route of administration, the gastrointestinal drugs market is segmented into rectal, parenteral, and oral.
By disease type, the gastrointestinal drugs market is segmented into inflammatory bowel disease, gastroesophageal reflux disease, and others. Of these, the gastroesophageal reflux disease will dominate the market over the forecast period.
By end user, the gastrointestinal drugs market is segmented into retail pharmacies, hospital pharmacies, and others.
Based on the region, the global gastrointestinal drugs market report covers the growth opportunities and recent trends across Europe, North America, the Asia Pacific (APAC), and the Middle East and Africa. Of these, North America will command the largest share in the market over the forecast period for increasing geriatric population, increasing lifestyle diseases, and favorable reimbursement policies.
The global gastrointestinal drugs market in Europe is predicted to hold the second-largest share over the forecast period for the launch of biosimilars for patent-confined brands available to heal inflammatory bowel disease/syndrome.
The global gastrointestinal drugs market in the APAC region is predicted to grow at a fast pace over the forecast period for increasing private & public investments for life sciences research and technological advancements in the healing process and treatment of gastrointestinal diseases/syndromes in China and India, and enhancement of the medical and healthcare infrastructure.
The global gastrointestinal drugs market in the MEA is predicted to have sound growth over the forecast period. Qatar, Kuwait, the UAE, and Saudi Arabia are the key contributors in the region.
Key players profiled in the global gastrointestinal drugs market report include Boehringer Ingelheim GmbH (Germany), GlaxoSmithKline Plc. (UK), Janssen Biotech (US), Sanofi (France), Valeant Pharmaceuticals (US), Eisai Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), Janssen Biotech Inc. (US), Bayer AG (Germany), Allergan Plc (US), Abbott Laboratories(US), Valeant (US), Johnson & Johnson (US), AstraZeneca (UK), and AbbVie Inc. (US).
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/gastrointestinal-drugs-market-558
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.